alexa Influence Of Recipient CYP3A5 Genotypes On The Pharmacokinetic Of Tacrolimus In Liver Transplant Recipients | 6824
ISSN: 2161-1076

Surgery: Current Research
Open Access

Like us on:

OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations
700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

Influence of recipient CYP3A5 genotypes on the pharmacokinetic of tacrolimus in liver transplant recipients

International Conference and Exhibition on Surgery, Anesthesia & Trichology

Kniepeiss Daniela

Accepted Abstracts: Surgery Curr Res

DOI: 10.4172/2161-1076.S1.010

Abstract
Tacrolimus shows high interindividual variability in pharmacokinetics. It is primarily metabolized by hepatic cytochrome P450 3A4 and 3A5 (CYP). In this study, we evaluated the influence of recipient CYP3A5 genotypes on the pharmacokinetics of Tacrolimus in patients after liver transplantation. Patients after liver transplantation with Tacrolimus maintenance therapy were included to the study. CYP3A5 genotypes of the recipients were established. Clinical and laboratory data at various time points (1 month, 3 months, 1 year and 3 years after start of medication with Tacrolimus) were evaluated retrospectively. Doses and trough levels of Tacrolimus were noted and a screening of all concomitant medications with possible CYP3A5 interaction was performed. SPSS for windows (release 14.0; SPSS, Inc) was used for statistical analyses. The criterion for statistical significance was p<0.05. Ninty-two liver transplant recipients participated in the study. CYP3A5 genotypes were successfully determined in all subjects and did not deviate from the Hardy-Weinberg equilibirum. 86% of the patients carried the CYP3A5 *3/*3 genotype and were thus classified as CYP3A5 non-expressors. 14% carried the CYP3A5 *1/*3 genotype and were classified as heterozygous expressors. No homozygous CYP3A5 expressor (*1/*1) was found. Neither Tacrolimus dose nor levels were significantly different between CYP3A5 expressors and non-expressors at any point of time (p=0.669, p=0.140, p=0.117, p=0.822). The pharmacokinetic of Tacrolimus in patients after liver transplantation is not influenced by the recipient CYP3A5 genotype. It is mostly the hepatic metabolism that contributes to the excretion of Tacrolimus. The donor CYP3A5 genotype might be useful to predict the Tacrolimus pharmacokinetic.
Biography
Kniepeiss Daniela has completed her M.D at the Medical University Graz, Austria and performed her fellowship in General Surgery and Subspeciality Training in Transplantation at the Department of Transplant Surgery, Medical University Graz, Austria. She has published papers in international journals and is reviewer for international journals. Research interests are reperfusion methods in liver transplantation, early detection of renal dysfunction in patients after liver transplantation, CYP3A5 genotypes and transplantation in elderly patients. Since 2011 she is leader of the research unit ?molecular transplantation medicine ?.
Leave Your Message 24x7
Top